An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 565-571

  Dréno, Brigitte ^a   Bettoli, Vincenzo ^b   Ochsendorf, Falk ^c   Perez Lopez, Montserrat ^d   Mobacken, Håkan ^e   Degreef, Hugo ^f   Layton, Allison ^g  

^a HÔTEL DIEU   (France)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HARROGATE AND DISTRICT NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Inflammatory acne; Oral antibiotics; Oral isotretinoin; Prognostic factors

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BENZOYL PEROXIDE; DOXYCYCLINE; ISOTRETINOIN; LYMECYCLINE; RETINOID;

ACNE; ALGORITHM; ARTICLE; CLINICAL PRACTICE; DEPRESSION; EUROPE; FAMILY HISTORY; HUMAN; MORBIDITY; PROGNOSIS; SCAR FORMATION; SKIN DEFECT; SOCIAL PSYCHOLOGY; SOCIAL STATUS;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; CONSENSUS; DERMATOLOGIC AGENTS; DERMATOLOGY; EUROPE; FEMALE; HUMANS; ISOTRETINOIN; MALE;

EID: 33845244380     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0030     Document Type: Article

References (68)

1. Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dreno B. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14(1): 4-12.
2. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107(5): 583-90.
3. Dalziel K, Parton S, Marks R. The effects of isotretinoin on follicular and sebaceous gland differentiation. Br J Dermatol 1987; 117: 317-23.
4. Leyden JJ, McGinley KJ. Effect of 13-cis-retinoic acid on sebum production and Propionibacterium acnes in severe nodulocystic acne. Arch Dermatol Res 1982; 272(3-4): 331-7.
5. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Summary information on a referral opinion following an arbitration pursuant to article 29 of Directive 2001/83/EC for isotretinoin. CPMP/8211/03, October 17, 2003.
6. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49(1 Suppl): S1-S37.
7. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European Expert Group on Oral Antibiotics in Acne. Eur J Dermatol 2004; 14(6): 391-9.
8. Ozolins M, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364(9452): 2188-95.
9. Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005; 9(1); (iii-212).
10. Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134(1): 107-13.
11. Herane MI, Andro I. Acne in infancy and acne genetics. Dermatology 2003; 206(1): 24-8.
12. Bataille V, Sneider H, MacGregor AJ. Sasieni P, Spector TD. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002; 119: 1317-22.
13. Palatsi R, Oikarinena A. Hormonal analysis and delayed hypersensitivity in identical twins with severe acne. Acta Derm Venereol (Stockh) 1979; 59: 157-60.
14. Cunliffe WJ. Natural history of acne. In: Marks R, ed. Acne and related disorders. London: M. Dunitz, 1989: 4-6.
15. Friedman GD. Twin studies of disease heritability based on medical records: application to acne vulgaris. Acta Genet Med Gemellol (Roma) 1984; 33: 487-95.
16. Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne - a twin study. Br J Dermatol 1988; 118: 393-6.
17. Swale VJ, Spector TD, Bataille VA. Sarcoidosis in monozygotic twins. Br J Dermatol 1998; 139(2): 350-2.
18. Evans DM, Kirk KM, Nyholt DR, Novac C, Martin NG. Teen-age acne is influenced by genetic factors. Br J Dermatol 2005; 152: 579-81.
19. Seukeran DC, Cunliffe WJ. Acne vulgaris in the elderly: the response to low-dose isotretinoin. Br J Dermatol 1998; 139(1): 99-101.
20. Vexiau P, Chivot M. Feminine acne: dermatologic disease or endocrine disease? Gynecol Obstet Fertil 2002; 30(1): 11-21.
21. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136(1): 66-70.
22. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999; 141: 297-300.
23. Biro FM, Lucky AW, Simbartl LA, Barton BA, Daniels SR, Striegel-Moore R, Kronsberg SS, Morrison JA. Pubertal maturation in girls and the relationship to anthropometric changes: pathways through puberty. J Pediatr 2003; 142(6): 643-6.
24. Chew EW, Bingham A, Burrows D. Incidence of acne vulgaris in patients with infantile acne. Clin Exp Dermatol 1990; 15(5): 376-7.
25. Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol 2004; 150(1): 72-81.
26. Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994; 19: 303-8.
27. Goodman GJ. Postacne scarring: a review of its pathophysiology and treatments. Dermatol Surg 2000; 26: 857-71.
28. Cunliffe WJ, Shuster S. The rate of sebum excretion in man. Br J Dermatol 1969; 81: 697-704.
29. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Inv Dermatol 1974; 62: 191-201.
30. Layton AM, Hughes BR, Macdonald Hull S, Eady EA, Cunliffe WJ. Seborrhoea-an indicator for poor clinical response in acne patients treated with antibiotics. Clin Ex Dermatol 1992; 17: 173-5.
31. Greenwood R, Burke B, Cunliffe WJ. Evaluation of a therapeutic strategy for the treatment of acne vulgaris with conventional therapy. Br J Dermatol 1986; 114: 353-8.
32. Eady EA, Cove JH, Blake J, et al. Recalcitrant acne vulgaris clinical biochemical and microbiological investigation of patients not responding to antibiotic treatment. Br J Dermatol 1988; 118: 415-23.
33. Plewig G, Kligman AM. Acne Conglobata. In: Plewig G, Kligman AM, eds. Acne and Rosacea. New York: Springer-Verlag Berlin Heidelberg, 1993: 270-7.
34. Mobacken H. Oral tetracycline treatment of acne. Rapid facial improvement, but back lesions are more difficult to treat. Lakartidningen 1993; 90(34): 2755-7.
35. Cunliffe WJ, Norris JFB. Isotretinoin-an explanation for its long-term benefit. Dermatologica 1987; 175(Suppl. 1): 133-7.
36. Berson DS. Current Concepts in the treatment of acne: a report from a clinical roundtable. Cutis 2003; 72: 5-13.
37. Thomas DR. Psychosocial effects of acne. J Cutan Med Surg 2004; 8(Suppl 4): 3-5.
38. Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett 2004; 9(7): 1; (3, 9).
39. Rapp DA, Brenes GA, Feldman SR, Fleischer Jr. AB, Graham GF, Dailey M, Rapp SR. Anger and acne: implications for quality of life, patient satisfaction and clinical care. Br J Dermatol 2004; 151(1): 183-9.
40. Pearl A, Arroll B, Lello J, Birchall NM. The impact of acne: a study of adolescents' attitudes, perception and knowledge. N Z Med J 1998; 111(1070): 269-71.
41. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999; 140(2): 273-82.
42. Hull PR, D'Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 2003; 4(7): 493-505.
43. Kellett SC, Gawkrodger DJ. A prospective study of the responsiveness of depression and suicidal ideation in acne patients to different phases of isotretinoin therapy. Eur J Dermatol 2005; 15(6): 484-8.
44. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001; 2(3): 135-41.
45. Sarazin F, Dompmartin A, Nivot S, Letessier D, Leroy D. Treatment of an infantile acne with oral isotretinoin. Eur J Dermatol 2004; 14(1): 71-2.
46. Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, Ravenscroft J, Vyakrnam S, Vowels B. Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology 1997; 195(Suppl 1): 4-9.
47. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 2001; 45(5): S188-S194.
48. Verschoore M. Hormonal aspects of acne. Ann Dermatol Venereol 1987; 114: 439-54.
49. Verschoore M. Hyperandrogenism and pilosebaceous follicles. Rev Prat 1993; 43: 2363-9.
50. Bekaert C, Song M, Delvigne A. Acne neonatorum and familial hyperandrogenism. Dermatology 1998; 196: 453-4.
51. Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne - a twin study. Br J Dermatol 1988; 118: 393-6.
52. Burket JM, Storrs FJ. Nodulocystic infantile acne occurring gin a kindred of steatocystoma. Arch Dermatol 1987; 123: 432-3.
53. Marr TJ, Traisman HS. Nodulocystic acne, chromosomal abnormality and diabetes mellitus. Cutis 1981; 27: 87-8.
54. Funderburk SJ, Landau JW. Acne in retarded boy with autosomal chromosomal abnormalitiy. Arch Dermatol 1976; 112: 859-61.
55. Voorhees JJ, Wilkins JW, Hayes E, Harrell R. Nodulocystic acne as a phenotypic feature of the XYY genotype. Arch Dermatol 1972; 105: 913-9.
56. Gonzalez T, Gantes M, Bustabad S, Diaz-Flores L. Acne fulminans associated with arthritis in monozygotic twins. J Rheumatol 1985; 12(2): 389-91.
57. Stewart ME, McDonnell MW, Downing DT. Possible genetic control of the proportions of branched-chain fatty acids in human sebaceous wax esters. J Invest Dermatol 1986; 86(6): 706-8;
58. (Schackert K, et al. Arch Dermatol 1974; 110(3): 468).
59. Wong SS, Pritchard MH, Holt PJ. Familial acne fulminans. Clin Exp Dermatol 1992; 17(5): 351-3.
60. Paraskevaidis A, Drakoulis N, Roots I, Orfanos CE, Zouboulis CC. Polymorphisms in the human cytochrome P-450 1A1 gene (CYP1A1) as a factor for developing acne. Dermatology 1998; 196(1): 171-5.
61. Wanner R, Zober A, Abraham K, Kleffe J, Henz BM, Wittig B. Polymorphism at codon 554 of the human Ah receptor: different allelic frequencies in Caucasians and Japanese and no correlation with severity of TCDD induced chloracne in chemical workers. Pharmacogenetics 1999; 9(6): 777-80.
62. Ostlere LS, Rumsby G, Holownia P, Jacobs HS, Rustin MH, Honour JW. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. Clin Endocrinol (Oxf) 1998; 48(2): 209-15.
63. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3(1): 9-15.
64. Hatta N, Dixon C, Ray AJ, Phillips SR, Cunliffe WJ, Dale M, Todd C, Meggit S, Birch-MacHin MA, Rees JL. Expression, candidate gene, and population studies of the melanocortin 5 receptor. J Invest Dermatol 2001; 116(4): 564-70.
65. Blanche H, Vexiau P, Clauin S, Le Gall I, Fiet J, Mornet E, Dausset J, Bellanne-Chantelot C. Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women. Hum Genet 1997; 101(1): 56-60.
66. Placzek M, Arnold B, Schmidt H, Gaube S, Keller E, Plewig G, Degitz K. Elevated 17-hydroxyprogesterone serum values in male patients with acne. J Am Acad Dermatol 2005; 53(6): 955-8.
67. Munro CS, Wilkie AO. Epidermal mosaicism producing localised acne: somatic mutation in FGFR2. Lancet 1998; 352(9129): 704-5.
68. Bekaert C, Song M, Delvigne A. Acne neonatorum and familial hyperandrogenism. Dermatology 1998; 196(4): 453-4.